This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated Sep 2026 quarter: revenue Rs 5,119.28 lakh vs Rs 7,667.24 lakh; profit Rs 154.46 lakh
VITAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts less than Nifty Microcap 250 and 1.2 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the consolidated quarter ended September 30, 2026, revenue from operations was Rs 5,119.28 lakh versus Rs 7,667.24 lakh a year earlier, down 33%, while profit after tax was Rs 154.46 lakh versus Rs 289.40 lakh, down 47%. A Rs 141.09 lakh one-off charge reduced pre-tax profit. Borrowings were Rs 7,942.05 lakh against equity of Rs 11,617.87 lakh. Two independent directors joined and two resigned.
Revenue and operating performance weakened, and the one-off charge cut profit. Borrowings remain below equity, but board turnover needs monitoring.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹49.98 Cr | ₹64.55 Cr | −22.6% |
| Operating profit | ₹1.36 Cr | ₹1.53 Cr | −11.2% |
| Profit after tax | ₹2.54 Cr | — | — |
| EBITDA margin | 8.6% | — | — |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.